Mereo BioPharma to be Acquired by Acelyrin for $150M

TL;DR

Mereo BioPharma is being bought by Acelyrin for $150M cash + milestones, expected Q3 close.

AI Summary

Mereo BioPharma Group plc announced on June 11, 2024, that it has entered into a definitive agreement to be acquired by Acelyrin, Inc. for approximately $150 million in cash, plus potential milestone payments. This transaction is expected to close in the third quarter of 2024, subject to customary closing conditions.

Why It Matters

This acquisition by Acelyrin, Inc. could lead to significant advancements in the development and commercialization of Mereo's pipeline drugs, potentially impacting patient access to new therapies.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, and there's a risk that these conditions may not be met, or that regulatory approvals could delay or prevent the transaction.

Key Numbers

• $150M — Acquisition Price (Cash consideration for Mereo BioPharma)

Key Players & Entities

• Mereo BioPharma Group plc (company) — Registrant
• Acelyrin, Inc. (company) — Acquiring company
• $150 million (dollar_amount) — Acquisition price
• June 11, 2024 (date) — Date of earliest event reported
• third quarter of 2024 (date) — Expected closing period

FAQ

Filing Documents

• d849907d8k.htm (8-K) — 34KB
• d849907dex991.htm (EX-99.1) — 25KB
• 0001193125-24-159393.txt ( ) — 237KB
• mreo-20240611.xsd (EX-101.SCH) — 3KB
• mreo-20240611_def.xml (EX-101.DEF) — 15KB
• mreo-20240611_lab.xml (EX-101.LAB) — 24KB
• mreo-20240611_pre.xml (EX-101.PRE) — 16KB
• d849907d8k_htm.xml (XML) — 6KB

Forward Looking Statements

Forward Looking Statements This Report contains "forward-looking statements." All statements other than statements of historical fact contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of the Company's operations or operating results. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on Mereo's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on Mereo. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting Mereo will be those that it anticipates. All of Mereo's forward-looking statements involve known and unknown risks and uncertainties some of which are significant or beyond its control and assumptions that could cause actual results to differ materially from Mereo BioPharma's historical experience and its present expectations or projections. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process; Mereo's reliance on third parties to conduct and provide funding for its clinical trials; Mereo's dependence on enrollment of patients in its clinical trials; and Mereo's dependence on its key executives. You should carefully consider the foregoing factors and the other risks and uncertainties that affect Mereo BioPharma's business, including those described in the "Risk Factors" section

Financial Statements and Exhibits

Financial Statements and Exhibits. The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed: (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release, dated June 11, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 11, 2024 MEREO BIOPHARMA GROUP PLC By: /s/ Charles Sermon Name: Charles Sermon Title: General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR